ESPE 2018 SATELLITE SYMPOSIUM MEETING REPORT

5 MEETING REPORT – ESPE 2018 SATELLITE SYMPOSIUM Insulin Treatment & Advanced Technology in the Management of Children with Diabetes The goals of insulin treatment are to reduce the time in hypoglycaemia and hyperglycaemia, and the degree of glycaemic variability, said Chiarelli. “And let me reiterate here that hyperglycaemia is as risky as hypoglycaemia. For decades we had thought that the main issue was hypoglycaemia, but now we know that hyperglycaemia is also dangerous for the brains of the children, particularly young children”. He added that glucose variability “is our enemy”, being damaging to the brain of the child in the short-term, as well as contributing to long-term complications. Chiarelli then gave an overview of the currently available insulins. Discussing the newest preparations in more detail, he noted that the two longest-acting insulins – glargine U300 and degludec – have very similar effects on glycemic control, with both having a relatively constant release rate into the blood rather than a distinct peak time when their concentration is highest . 1 Recent Long-Acting Insulins And turning to the latest in short-acting insulins, he noted topline, not-yet-published results showing that faster-acting insulin aspart is “efficacious and safe” when compared with NovoRapid ® in children and adolescents with type 1 diabetes. “So I think that we as paediatricians should say that insulin treatment in children is easier today”, said Chiarelli. “Of course education is paramount from the very beginning”, he added, and also reminded the audience of the need to regularly check injection sites and patients’ techniques and skills. Heise T et al. et al., Diabetes Obes Metab 2017; Bolli GB et al., Diabetes Care 2015 Recent Long- cting In ulins